Compare Stocks: LLY, JNJ, NVO, and LLY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$255.26 +0.3%	$246.74	$169.65 ▼ $274.90	$613.10B	0.24	8.17 million shs	7.30 million shs
LLY Eli Lilly and Company	$1,115.68 -0.5%	$1,154.75	$623.78 ▼ $1,249.45	$1.06T	0.51	2.38 million shs	4.08 million shs
LLY Eli Lilly and Company	$1,115.68 -0.5%	$1,154.75	$623.78 ▼ $1,249.45	$1.06T	0.51	2.38 million shs	4.08 million shs
NVO Novo Nordisk A/S	$44.16 -6.2%	$46.96	$35.12 ▼ $64.16	$210.26B	0.76	9.57 million shs	47.34 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.77%	-4.44%	-3.04%	+12.83%	+52.12%
LLY Eli Lilly and Company	-2.35%	-6.31%	-7.12%	+13.48%	+47.39%
LLY Eli Lilly and Company	-2.35%	-6.31%	-7.12%	+13.48%	+47.39%
NVO Novo Nordisk A/S	-0.18%	-5.06%	-6.49%	+5.00%	-2.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$255.26 +0.3%	$246.74	$169.65 ▼ $274.90	$613.10B	0.24	8.17 million shs	7.30 million shs
LLY Eli Lilly and Company	$1,115.68 -0.5%	$1,154.75	$623.78 ▼ $1,249.45	$1.06T	0.51	2.38 million shs	4.08 million shs
LLY Eli Lilly and Company	$1,115.68 -0.5%	$1,154.75	$623.78 ▼ $1,249.45	$1.06T	0.51	2.38 million shs	4.08 million shs
NVO Novo Nordisk A/S	$44.16 -6.2%	$46.96	$35.12 ▼ $64.16	$210.26B	0.76	9.57 million shs	47.34 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	-0.77%	-4.44%	-3.04%	+12.83%	+52.12%
LLY Eli Lilly and Company	-2.35%	-6.31%	-7.12%	+13.48%	+47.39%
LLY Eli Lilly and Company	-2.35%	-6.31%	-7.12%	+13.48%	+47.39%
NVO Novo Nordisk A/S	-0.18%	-5.06%	-6.49%	+5.00%	-2.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$267.48	4.79% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,283.64	15.05% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,283.64	15.05% Upside
NVO Novo Nordisk A/S	2.14	Hold	$65.56	48.46% Upside

Current Analyst Ratings Breakdown

Latest LLY, JNJ, NVO, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	JNJ Johnson & Johnson	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$280.00
8/3/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	JNJ Johnson & Johnson	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$272.00 ➝ $282.00
7/29/2026	JNJ Johnson & Johnson	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$300.00
7/24/2026	JNJ Johnson & Johnson	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
7/20/2026	NVO Novo Nordisk A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/20/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/17/2026	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$270.00
7/16/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy	$280.00
7/16/2026	JNJ Johnson & Johnson	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$305.00
7/16/2026	JNJ Johnson & Johnson	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$258.00 ➝ $265.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$94.19B	6.53	$14.17 per share	18.02	$35.26 per share	7.24
LLY Eli Lilly and Company	$65.18B	16.12	$25.01 per share	44.61	$28.07 per share	39.75
LLY Eli Lilly and Company	$65.18B	16.12	$25.01 per share	44.61	$28.07 per share	39.75
NVO Novo Nordisk A/S	$46.80B	4.21	$4.39 per share	10.05	$6.58 per share	6.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.63	29.58	19.93	2.41	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	39.63	24.80	1.39	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	39.63	24.80	1.39	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.37	13.50	4.29	37.23%	63.31%	22.19%	8/5/2026 (Estimated)

Latest LLY, JNJ, NVO, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.06	N/A	N/A	N/A	$20.69 billion	N/A
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.06	N/A	N/A	N/A	$20.69 billion	N/A
8/4/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.9440	+$0.1740	$0.72	$10.90 billion	$11.98 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	2.12%	+5.25%	62.11%	64 Years
LLY Eli Lilly and Company	$6.92	0.62%	+15.18%	24.58%	11 Years
LLY Eli Lilly and Company	$6.92	0.62%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.75	3.68%	+21.74%	41.08%	N/A

Latest LLY, JNJ, NVO, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.63%	8/14/2026	8/14/2026	9/10/2026
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.63%	8/14/2026	8/14/2026	9/10/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.17%	8/25/2026	8/25/2026	9/8/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
LLY Eli Lilly and Company	1.26	1.50	1.10
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

LLY, JNJ, NVO, and LLY Headlines

Recent News About These Companies

Novo Nordisk A/S (NYSE:NVO) Stock Price Down 6.1% - Here's Why

4 hours ago | marketbeat.com

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

August 4 at 3:15 PM | finance.yahoo.com

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook

August 4 at 3:15 PM | finance.yahoo.com

Novo Nordisk Q2 2026 earnings beat, raises full-year outlook

August 4 at 3:15 PM | qz.comQ

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

August 4 at 3:15 PM | finance.yahoo.com

Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats Up

August 4 at 3:15 PM | finance.yahoo.com

Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes

August 4 at 3:08 PM | invezz.comI

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

August 4 at 2:16 PM | barrons.com

Novo Nordisk shares slide after guidance disappoints investors

August 4 at 1:30 PM | cnbc.com

Novo Nordisk A/S (NYSE:NVO) Announces Earnings Results

August 4 at 1:10 PM | marketbeat.com

Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost

August 4 at 1:03 PM | wsj.com

Novo Nordisk's Q2 profit beats forecasts, raises outlook

August 4 at 1:00 PM | reuters.com

Novo Nordisk Probes Thyroid Cancer Risk in Real‑World GLP‑1 Users

August 4 at 12:51 PM | tipranks.com

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

August 4 at 11:11 AM | tipranks.com

‘Arrogance kills’: Novo chief injects risk-taking into Ozempic maker

August 4 at 9:40 AM | finance.yahoo.com

Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.

August 4 at 9:40 AM | finance.yahoo.com

H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development

August 4 at 9:40 AM | finance.yahoo.com

Quantinno Capital Management LP Buys 33,006 Shares of Novo Nordisk A/S $NVO

August 4 at 4:56 AM | marketbeat.com

Eastern Bank Trims Stock Holdings in Novo Nordisk A/S $NVO

August 4 at 4:07 AM | marketbeat.com

Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

August 3 at 1:37 PM | proactiveinvestors.com

Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

August 3 at 1:37 PM | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, JNJ, NVO, and LLY Company Descriptions

Johnson & Johnson NYSE:JNJ

$255.26 +0.85 (+0.33%)

Closing price 03:59 PM Eastern

Extended Trading

$255.20 -0.06 (-0.03%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$1,115.68 -5.68 (-0.51%)

Closing price 03:59 PM Eastern

Extended Trading

$1,129.00 +13.32 (+1.19%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company NYSE:LLY

$1,115.68 -5.68 (-0.51%)

Closing price 03:59 PM Eastern

Extended Trading

$1,129.00 +13.32 (+1.19%)

As of 07:59 PM Eastern

Novo Nordisk A/S NYSE:NVO

$44.16 -2.93 (-6.22%)

Closing price 03:59 PM Eastern

Extended Trading

$44.68 +0.51 (+1.16%)

As of 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, JNJ, NVO, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, JNJ, NVO, and LLY Earnings

Compare Dividends

Latest LLY, JNJ, NVO, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, JNJ, NVO, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, JNJ, NVO, and LLY Company Descriptions

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools